---
audienceLevel: patient
cancerTypes:
- colorectal
- skin
- pancreatic
- liver
- ovarian
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Cancer Treatment Research - NCI
url: https://www.cancer.gov/about-cancer/treatment/research
version: v1
---

# Cancer Treatment Research - NCI

# Treatment Research

- [Combination Immunotherapy Shrank a Variety of Metastatic Solid Cancers](/news-events/press-releases/2025/combination-immunotherapy-shrinks-solid-tumors)

Posted: April 1, 2025

A new form of personalized cancer immunotherapy, known as tumor infiltrating lymphocyte (TIL) therapy, dramatically improved the treatment’s effectiveness in patients with metastatic gastrointestinal cancers.
- [Experimental Treatment Uses Engineered Fat Cells to “Starve” Tumors](/news-events/cancer-currents-blog/2025/starving-tumors-engineered-fat-cells)

Posted: March 27, 2025

Researchers have developed a form of cancer treatment that uses fat cells engineered to aggressively consume nutrients like glucose. When implanted in mice, the engineered cells appeared to outcompete tumors for nutrients, shrinking tumors.
- [Can AI Help Predict Which Cancer Patients Should Be Treated with Immunotherapy?](/news-events/cancer-currents-blog/2025/ai-predicts-cancer-immunotherapy-response-survival)

Posted: February 26, 2025

An AI-based tool called SCORPIO more accurately predicted whether cancer patients’ tumors would respond to checkpoint inhibitors than currently available tests, a new study found. It also predicted how long patients would live after treatment.
- [CAR T Cells: Engineering Patients’ Immune Cells to Treat Their Cancers](/about-cancer/treatment/research/car-t-cells)

Updated: February 26, 2025

Research to improve CAR T-cell therapy is progressing rapidly. Researchers are working to expand its use to treat more types of cancer and better understand and manage its side effects. Learn how CAR T-cell therapy works, which cancers it’s used to treat, and current research efforts.
- [Treatment Strategy for ecDNA-Driven Tumors Shows Potential](/news-events/cancer-currents-blog/2024/targeting-ecdna-in-tumors)

Posted: December 5, 2024

Researchers have found that cancer cells containing extrachromosomal DNAs (ecDNAs) have a weakness that can be exploited by a drug that targets the CHK1 protein. In mice, combining the drug with another targeted therapy kept cancer at bay for long periods.
- [Will Ponsegromab Be a Game Changer for Cancer Cachexia?](/news-events/cancer-currents-blog/2024/ponsegromab-cancer-cachexia)

Posted: October 17, 2024

In a clinical trial, people with advanced cancer and cachexia treated with the experimental drug ponsegromab gained an average of 2 to 6 pounds over 12 weeks, depending on the dose they received. Participants treated with the placebo lost an average of 1 pound over the same time period.
- [As More People with Cancer Use Medical Cannabis, Oncologists Face Questions They Struggle to Answer](/news-events/cancer-currents-blog/2024/medical-cannabis-oncologists-patients-communication)

Posted: October 16, 2024

Up to 40% of people being treated for cancer use cannabis to help with side effects like pain and anxiety. But with evidence from studies on cannabis lacking, clinicians feel ill-equipped to answer patient questions about its safety and effectiveness.
- [To Combat Cancer Treatment Resistance, Researchers Try Leveraging Evolution](/news-events/cancer-currents-blog/2024/cancer-treatment-resistance-engineering-evolution)

Posted: August 22, 2024

Scientists have developed a strategy for treating cancer that takes advantage of tumors’ ability to rapidly evolve and turns it against them. It involves intentionally making some tumor cells resistant to a specific treatment from the get-go.
- [Understanding the Risk of Second Cancers After CAR T-Cell Therapy](/news-events/cancer-currents-blog/2024/car-t-cell-therapy-second-cancers)

Posted: August 13, 2024

In late 2023, FDA announced it was investigating instances of second cancers following treatment with CAR T-cell therapies. In this Q&A, NCI’s Dr. Stephanie Goff explains what’s known about the issue, stressing that second cancers “of any kind are rare.”
- [Drug Combo JAKs Up Immunotherapy in Two Clinical Trials](/news-events/cancer-currents-blog/2024/jak-inhibitor-improves-cancer-immunotherapy)

Posted: August 8, 2024

Scientists have been searching for ways to make immune checkpoint inhibitors work for more patients. In two trials, researchers explored a possible role for JAK inhibitors, which dampen chronic inflammation.
- [Immunotherapy approach shows potential in some people with metastatic solid tumors](/news-events/press-releases/2024/personalized-immunotherapy-shrinks-solid-tumors)

Posted: July 11, 2024

A new cellular immunotherapy approach shrank tumors in 3 of 7 patients with metastatic colon cancer, in a small NCI clinical trial. Normal white blood cells from each patient were genetically engineered to produce receptors that recognize and attack their specific cancer cells.
- [Spurred by Survivors, Researchers Are Revisiting Cancer Drug Doses](/news-events/cancer-currents-blog/2024/cancer-drugs-lower-doses)

Posted: June 5, 2024

When it comes to cancer drugs, researchers are moving away from a paradigm called the maximum tolerated dose. Instead, they’re focusing more on identifying doses that produce fewer side effects but are still effective against a person’s cancer.
- [Leading Change in Cancer Clinical Research, Because Our Patients Can’t Wait](/news-events/cancer-currents-blog/2024/clinical-trials-cancer-inviting-innovation)

Posted: May 31, 2024

Reshaping the cancer clinical trials infrastructure to overcome key bottlenecks will involve embracing technology and collaboration, and inviting innovation, explain NCI Director Dr. W. Kimryn Rathmell and NCI Special Advisor Dr. Shaalan Beg.
- [Manipulating an Immune Cell May Make Radiation Therapy More Effective, Study Suggests](/news-events/cancer-currents-blog/2024/radiation-cancer-bambi-immune-response)

Posted: February 12, 2024

In a new study in mice, researchers showed they could enhance radiation therapy by boosting levels of the BAMBI protein in MDSC immune cells in the tumor microenvironment. After radiation, T cells flooded into the tumor and killed tumors elsewhere in the body.
- [Virtual Mind–Body Fitness Classes Show Unexpected Benefit in People with Cancer](/news-events/cancer-currents-blog/2023/mind-body-fitness-cancer-side-effects)

Posted: December 15, 2023

In a clinical trial, people being treated for cancer who participated in virtual mind–body fitness classes were less likely to be hospitalized, and had shorter stays when they were hospitalized, than people who did not take the classes.
- [What Comes after NCI-MATCH? NCI’s New Precision Medicine Cancer Trials](/news-events/cancer-currents-blog/2023/new-nci-precision-medicine-trials)

Posted: December 6, 2023

NCI’s James H. Doroshow, M.D., reflects on the accomplishments of NCI-MATCH, a first-of-its-kind precision medicine cancer trial, and gives an overview of three new successor trials: ComboMATCH, MyeloMATCH, and iMATCH.
- [A Better Biomarker for Cancer Immunotherapy?](/news-events/cancer-currents-blog/2023/immunotherapy-mismatch-repair-biomarker)

Posted: November 3, 2023

A new study, conducted largely in mice, may help explain why a currently used molecular marker—called mismatch repair deficiency—doesn’t always work to predict which patients will respond to immunotherapies called immune checkpoint inhibitors.
- [NCI researchers develop approach that could help supercharge T-cell therapies against solid tumors](/news-events/press-releases/2023/cytokines-supercharge-t-cell-therapies)

Posted: November 1, 2023

New approach may increase the effectiveness of T-cell-based immunotherapy treatments against solid tumors.
- [Oncolytic Virus Enables the Immune System to Attack Tumors](/news-events/cancer-currents-blog/2023/oncolytic-virus-blocking-tgf-beta)

Posted: October 12, 2023

A cancer-infecting virus engineered to tamp down a tumor’s ability to suppress the immune system shrank tumors in mice, a new study shows. The modified oncolytic virus worked even better when used along with an immune checkpoint inhibitor.
- [Few People with Cancer Undergo Testing for Inherited Gene Mutations](/news-events/cancer-currents-blog/2023/germline-testing-for-cancer-underused)

Posted: August 1, 2023

Despite recommendations, a new analysis shows few people with cancer undergo germline testing to learn if their cancer may have been caused by gene changes inherited from a parent. Germline testing can help doctors determine the best treatments for a patient and help identify people whose family members may be at higher risk of cancer.
- [NCI's ComboMATCH Initiative Will Test New Drug Combinations Guided by Tumor Biology](/news-events/press-releases/2023/combomatch-precision-medicine-cancer-initiative)

Posted: June 1, 2023

ComboMATCH will consist of numerous phase 2 cancer treatment trials that aim to identify promising drug combinations that can advance to larger, more definitive clinical trials.
- [Multiple mRNA Vaccines Show Promise for Treating HPV-Related Cancers](/news-events/cancer-currents-blog/2023/mrna-vaccines-treat-hpv-cancers)

Posted: April 26, 2023

A new study has compared three formulations of an mRNA vaccine designed to treat cancers caused by human papillomavirus (HPV) infections. All three vaccines showed promise in mice.
- [Strategy May Prevent Tumor Resistance to Targeted Cancer Therapies](/news-events/cancer-currents-blog/2023/preventing-resistance-cancer-targeted-therapies)

Posted: March 17, 2023

Researchers have identified a mechanism by which cancer cells develop specific genetic changes needed to become resistant to targeted therapies. They also showed that this process, called non-homologous end-joining (NHEJ), can potentially be disrupted.
- [Immunotherapy and… Nothing Else? Studies Test Potential Paradigm Shift in Cancer Treatment](/news-events/cancer-currents-blog/2023/neoadjuvant-immunotherapy-only-treatment)

Posted: February 23, 2023

For some people with cancer, is 6 months of immunotherapy the only treatment they might ever need? Or 4 weeks of immunotherapy followed by minor surgery? Results from several small clinical trials suggest these scenarios may be bona fide possibilities.
- [Studies Test CAR T-Cell Therapies Designed to Overcome Key Limitations](/news-events/cancer-currents-blog/2023/car-t-cell-therapies-overcoming-limitations)

Posted: February 8, 2023

Two research teams have developed ways of overcoming barriers that have limited the effectiveness of CAR T-cell therapies, including engineering ways to potentially make them effective against solid tumors like pancreatic cancer and melanoma.
- [Study Identifies a Potential Cause of Immunotherapy’s Heart-Related Side Effects](/news-events/cancer-currents-blog/2022/immunotherapy-myocarditis-cause)

Posted: December 22, 2022

In people with cancer treated with immune checkpoint inhibitors, a rare, but often fatal, side effect is inflammation in the heart, called myocarditis. Researchers have now identified a potential chief cause of this problem: T cells attacking a protein in heart cells called α-myosin.
- [Can Chemotherapy Drugs Be Designed to Avoid Side Effects?](/news-events/cancer-currents-blog/2022/tumor-targeted-chemo-drp-104-avoids-side-effects)

Posted: December 16, 2022

Researchers have modified a chemo drug, once abandoned because it caused serious gut side effects, so that it is only triggered in tumors but not normal tissues. After promising results in mice, the drug, DRP-104, is now being tested in a clinical trial.
- [Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy?](/news-events/cancer-currents-blog/2022/kras-targeted-drugs-as-immunotherapy)

Posted: October 31, 2022

Two research teams have developed a treatment approach that could potentially enable KRAS-targeted drugs—and perhaps other targeted cancer drugs—flag cancer cells for the immune system. In lab studies, the teams paired these targeted drugs with experimental antibody drugs that helped the immune system mount an attack.
- [Targeting Inflammation Emerges as a Strategy for Treating Cancer](/news-events/cancer-currents-blog/2022/reducing-inflammation-to-treat-cancer)

Posted: August 19, 2022

Inflammation is considered a hallmark of cancer. Researchers hope to learn more about whether people with cancer might benefit from treatments that target inflammation around tumors. Some early studies have yielded promising results and more are on the horizon.
- [Disguising Cancer as an Infection Helps the Immune System Eliminate Tumors](/news-events/cancer-currents-blog/2022/cancer-immunotherapy-cmv-peptides)

Posted: July 22, 2022

NCI researchers are developing an immunotherapy that involves injecting protein bits from cytomegalovirus (CMV) into tumors. The proteins coat the tumor, causing immune cells to attack. In mice, the treatment shrank tumors and kept them from returning.
- [Dabrafenib–Trametinib Combination Approved for Solid Tumors with BRAF Mutations](/news-events/cancer-currents-blog/2022/fda-dabrafenib-trametinib-braf-solid-tumors)

Posted: July 21, 2022

FDA has approved the combination of the targeted drugs dabrafenib (Tafinlar) and trametinib (Mekinist) for nearly any type of advanced solid tumor with a specific mutation in the BRAF gene. Data from the NCI-MATCH trial informed the approval.
- [Immunotherapy’s Skin Side Effects: Are Microbes to Blame?](/news-events/cancer-currents-blog/2022/cancer-immunotherapy-skin-side-effects-microbes)

Posted: July 13, 2022

People with cancer who take immunotherapy drugs often develop skin side effects, including itching and painful rashes. New research in mice suggests these side effects may be caused by the immune system attacking new bacterial colonies on the skin.
- [Implanted “Drug Factories” Deliver Cancer Treatment Directly to Tumors](/news-events/cancer-currents-blog/2022/implanted-drug-factories-il2-ovarian-cancer)

Posted: April 7, 2022

Researchers have developed tiny “drug factories” that produce an immune-boosting molecule and can be implanted near tumors. The pinhead-sized beads eliminated tumors in mice with ovarian and colorectal cancer and will soon be tested in human studies.
- [Severe Side Effects of Cancer Treatment Are More Common in Women than Men](/news-events/cancer-currents-blog/2022/cancer-treatment-women-severe-side-effects)

Posted: March 15, 2022

Women are more likely than men to experience severe side effects from cancer treatments such as chemotherapy, targeted therapy, and immunotherapy, a new study finds. Researchers hope the findings will increase awareness of the problem and help guide patient care.
- [Telehealth-Based Cancer Care Surged during COVID. Will It Continue?](/news-events/cancer-currents-blog/2022/pandemic-telehealth-surge-cancer-care)

Posted: March 9, 2022

Experts say studies are needed on how to best transition telehealth from a temporary solution during the pandemic to a permanent part of cancer care that’s accessible to all who need it.
- [Can Chronic Graft-Versus-Host Disease Be Prevented?](/news-events/cancer-currents-blog/2022/chronic-gvhd-naive-t-cell-depletion)

Posted: February 17, 2022

Removing immune cells called naive T cells from donated stem cells before they are transplanted may prevent chronic graft-versus-host disease (GVHD) in people with leukemia, a new study reports. The procedure did not appear to increase the likelihood of patients’ cancer returning.
- [Cancer Immunotherapies Don’t Work for Everyone: HLA Gene May Explain Why](/news-events/cancer-currents-blog/2022/immunotherapy-cancer-biomarker-hla-gene)

Posted: January 27, 2022

A specific form of the HLA gene, HLA-A\*03, may make immune checkpoint inhibitors less effective for some people with cancer, according to an NCI-led study. If additional studies confirm the finding, it could help guide the use of these commonly used drugs.
- [Can mRNA Vaccines Help Treat Cancer?](/news-events/cancer-currents-blog/2022/mrna-vaccines-to-treat-cancer)

Posted: January 20, 2022

The success of mRNA vaccines for COVID-19 could help accelerate research on using mRNA vaccine technology to treat cancer, including the development of personalized cancer vaccines.
- [Extra or Missing Chromosomes May Help Cancer Cells Survive Treatment](/news-events/cancer-currents-blog/2021/aneuploidy-cancer-treatment-resistance)

Posted: September 24, 2021

Aneuploidy—when cells have too many or too few chromosomes—is common in cancer cells, but scientists didn’t know why. Two new studies suggest that aneuploidy helps the cells survive treatments like chemotherapy and targeted therapies.
- [Gut Microbes May Influence How Well Radiation Therapy Works against Cancer](/news-events/cancer-currents-blog/2021/cancer-fungi-gut-radiation-therapy)

Posted: September 2, 2021

New research suggests that fungi in the gut may affect how tumors respond to cancer treatments. In mice, when bacteria were eliminated with antibiotics, fungi filled the void and impaired the immune response after radiation therapy, the study found.
- [FDA Approves Belumosudil to Treat Chronic Graft-Versus-Host Disease](/news-events/cancer-currents-blog/2021/fda-belumosudil-rezurock-chronic-gvhd)

Posted: August 18, 2021

FDA has approved belumosudil (Rezurock) for the treatment of chronic graft-versus-host disease (GVHD). The approval covers the use of belumosudil for people 12 years and older who have already tried at least two other therapies.
- [Can an Antibiotic Treat Cancers that Become Resistant to PARP Inhibitors?](/news-events/cancer-currents-blog/2021/novobiocin-cancer-parp-inhibitor-resistance-1)

Posted: July 27, 2021

In lab studies, the antibiotic novobiocin showed promise as a treatment for cancers that have become resistant to PARP inhibitors. The drug, which inhibits a protein called DNA polymerase theta, will be tested in NCI-supported clinical trials.
- [Avasopasem Shields Normal Cells from Radiation, Helps Kill Cancer Cells](/news-events/cancer-currents-blog/2021/avasopasem-cancer-radiation-more-effective)

Posted: June 23, 2021

A drug called avasopasem manganese, which has been found to protect normal tissues from radiation therapy, can also make cancer cells more vulnerable to radiation treatment, a new study in mice suggests.
- [Study Details Long-Term Side Effects of Immune Checkpoint Inhibitors](/news-events/cancer-currents-blog/2021/immune-checkpoint-inhibitors-melanoma-long-term-side-effects)

Posted: April 30, 2021

While doctors are familiar with the short-term side effects of immune checkpoint inhibitors, less is known about potential long-term side effects. A new study details the chronic side effects of these drugs in people who received them as part of treatment for melanoma.
